Andra AP fonden Invests $42.72 Million in Abbott Laboratories $ABT

Andra AP fonden purchased a new stake in Abbott Laboratories (NYSE:ABT) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 318,908 shares of the healthcare product maker’s stock, valued at approximately $42,715,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ABT. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the third quarter worth about $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $31,000. Anfield Capital Management LLC increased its holdings in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. Delos Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories during the 2nd quarter valued at approximately $32,000. Finally, Bridge Generations Wealth Management LLC bought a new position in Abbott Laboratories during the third quarter worth $33,000. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on ABT shares. Leerink Partners lowered their target price on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Oppenheimer lowered their price objective on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. The Goldman Sachs Group lowered their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Daiwa Securities Group dropped their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Finally, BTIG Research reduced their price target on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $137.05.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Analyst/bullish research: A Seeking Alpha piece argues Abbott’s recent pullback is a buying opportunity, citing attractive profitable-growth characteristics and positioning for recovery. Abbott’s Meltdown Is Worth Buying
• Positive Sentiment: Income and steady growth pitch: The Motley Fool highlights Abbott as a steady income stock with double‑digit earnings growth and a dependable dividend, supporting longer-term total‑return appeal. Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
• Neutral Sentiment: Valuation snapshot shows mixed signals: A Yahoo Finance valuation piece notes short‑term momentum has been weak and longer‑term returns negative, leaving conflicting “fair value” signals for investors to reconcile. Assessing Abbott Laboratories (ABT) Valuation
• Neutral Sentiment: Peer comparison: Coverage comparing Abbott to Intuitive Surgical frames Abbott as the steadier, dividend‑paying medtech pick, while Intuitive may offer higher growth from procedural/robotics expansion — useful for portfolio allocation but not an immediate earnings shock. Intuitive Surgical or Abbott: Which MedTech Stock Is a Better Bet Now?
• Neutral Sentiment: Sector noise from diagnostics peers: A large drop in Grail’s stock after trial updates is creating headline risk for diagnostics names; this may press sentiment in the broader diagnostics/medtech complex but does not directly change Abbott’s fundamentals. Grail’s Stock Dropped 50% on Friday
• Negative Sentiment: Underperformance and analyst skepticism: Multiple pieces note ABT has underperformed the Nasdaq and that some research houses have trimmed price targets and flagged execution/earnings-translation risk — pressure that can weigh on sentiment until clarity on growth drivers. Is Abbott Laboratories Stock Underperforming the Nasdaq?
• Negative Sentiment: Split analyst views driving volatility: A market narrative piece documents a wide range of recent price‑target moves (some cuts, at least one raise into the mid‑$150s), leaving investors with conflicting signals and more volatile price action. How The Evolving Wall Street Narrative Is Reframing Abbott Laboratories (ABT) Valuation Prospects

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the purchase, the director owned 6,738,817 shares in the company, valued at $732,711,572.41. This represents a 0.15% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT opened at $116.21 on Friday. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.24. The company has a market capitalization of $201.94 billion, a price-to-earnings ratio of 31.24, a P/E/G ratio of 1.83 and a beta of 0.75. The business’s 50-day moving average is $117.53 and its 200-day moving average is $125.41.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The firm had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the prior year, the company posted $1.34 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.